Biopharmaceutical Excipients Market Research Report—Global Forecast till 2027

Biopharmaceutical Excipients Market Size, Trends and Growth Outlook By Product {Solubilizers & Surfactants/Emulsifiers (Triglycerides, Esters), Polyols (Mannitol, Sorbitol), Carbohydrates (Sucrose, Dextrose, Starch), Specialty Excipients}, Formulation (Oral, Topical, Injectables) and Region (North America, Europe, Asia-Pacific, Rest of the World)—Forecast to 2027

ID: MRFR/HC/9128-HCR | June 2021 | Region: Global | 120 Pages         

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Cellulite Type

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Regional Impact

5.3.4. Opportunity and Threat Analysis

6. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT

6.1. Overview

6.2. Solubilizers & Surfactants/Emulsifiers

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.2.1. Triglycerides

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.2.2. Esters

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.2.3. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3. Polyols

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3.1. Mannitol

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3.2. Sorbitol

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3.3. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4. Carbohydrates

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4.1. Sucrose

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4.2. Dextrose

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4.3. Starch

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4.4. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION

7.1. Overview

7.2. Oral

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.3. Topical

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.4. Injectables

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY REGION

8.1. Overview

8.2. North America

8.2.1. US

8.2.2. Canada

8.3. Europe

8.3.1. Germany

8.3.2. France

8.3.3. Italy

8.3.4. Spain

8.3.5. UK

8.3.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Rest of the World

8.5.1. Middle East

8.5.2. Africa

8.5.3. Latin America

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Biopharmaceutical Excipients Market

9.5. Competitive Benchmarking

9.6. Leading Players in terms of number of developments in the Global Biopharmaceutical Excipients Market

9.7. Key developments and Growth Strategies

9.7.1. New ProductLaunch/Service Deployment

9.7.2. Merger &Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2020

9.8.2. Major Players R&D Expenditure, 2020

10. COMPANY PROFILES

10.1. Merck KGaA

10.1.1. Company Overview

10.1.2. Product Offered

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Colorcon (BPSI Holdings Inc)

10.2.1. Company Overview

10.2.2. Products Offered

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. BASF SE

10.3.1. Company Overview

10.3.2. Products Offered

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Associated British Foods plc

10.4.1. Company Overview

10.4.2. Products Offered

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Signet Excipients Pvt. Ltd (IMCD)

10.5.1. Company Overview

10.5.2. Products Offered

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Sigachi Industries Limited

10.6.1. Company Overview

10.6.2. Products Offered

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Spectrum Chemical Manufacturing Corp.

10.7.1. Company Overview

10.7.2. Products Offered

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Roquette Frères

10.8.1. Company Overview

10.8.2. Products Offered

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Clariant

10.9.1. Company Overview

10.9.2. Products Offered

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. DFE Pharma

10.10.1. Company Overview

10.10.2. Products Offered

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. J. Rettenmaier & Söhne GmbH + Co Kg

10.11.1. Company Overview

10.11.2. Products Offered

10.11.3. Financial Overview

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

10.12. Evonik Industries AG

10.12.1. Company Overview

10.12.2. Products Offered

10.12.3. Financial Overview

10.12.4. Key Developments

10.12.5. SWOT Analysis

10.12.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SYNOPSIS, 2018–2027

TABLE 2 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET ESTIMATES &FORECAST, 2018–2027 (USD MILLION)

TABLE 3 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, BYPRODUCT, 2018–2027 (USD MILLION)

TABLE 4 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 5 NORTH AMERICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 6 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 7 US: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 8 US BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 9 CANADA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, PRODUCT, 2018–2027 (USD MILLION)

TABLE 10 CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 11 EUROPE: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 12 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 13 GERMANY: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 14 GERMANY: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 15 FRANCE: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 16 FRANCE: BIOPHARMACEUTICAL EXCIPIENTS MARKET, FORMULATION, 2018–2027 (USD MILLION)

TABLE 17 ITALY: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 18 ITALY: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 19 SPAIN: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 20 SPAIN: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 21 UK: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 22 UK: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 23 REST OF EUROPE: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 24 REST OF EUROPE: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 25 ASIA-PACIFIC: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 26 ASIA-PACIFIC: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 27 JAPAN: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 28 JAPAN: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 29 CHINA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 30 CHINA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 31 INDIA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 32 INDIA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 33 AUSTRALIA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 34 AUSTRALIA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, FORMULATION2018–2027 (USD MILLION)

TABLE 35 SOUTH KOREA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 36 SOUTH KOREA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION2018–2027 (USD MILLION)

TABLE 37 REST OF ASIA-PACIFIC: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 38 REST OF ASIA-PACIFIC: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018–2027 (USD MILLION)

TABLE 39 REST OF THE WORLD: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 40 REST OF THE WORLD: BIOPHARMACEUTICAL EXCIPIENTS MARKET, FORMULATION2018–2027 (USD MILLION)

TABLE 41 MIDDLE EAST: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 42 MIDDLE EAST: BIOPHARMACEUTICAL EXCIPIENTS MARKET, FORMULATION2018–2027 (USD MILLION)

TABLE 43 AFRICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 44 AFRICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION2018–2027 (USD MILLION)

TABLE 45 LATIN AMERICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018–2027 (USD MILLION)

TABLE 46 LATIN AMERICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION2018–2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET

FIGURE 4 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY PRODUCT, 2020 (%)

FIGURE 5 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY FORMULATION, 2020 (%)

FIGURE 6 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 NORTH AMERICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 EUROPE: BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 ASIA-PACIFIC: BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 REST OF THE WORLD: BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 12 MERCK KGAA.: KEY FINANCIALS

FIGURE 13 MERCK KGAA.: SEGMENTAL REVENUE

FIGURE 14 MERCK KGAA.: REGIONAL REVENUE

FIGURE 15 COLORCON: KEY FINANCIALS

FIGURE 16 COLORCON: SEGMENTAL REVENUE

FIGURE 17 COLORCON: REGIONAL REVENUE

FIGURE 18 BASF SE: KEY FINANCIALS

FIGURE 19 BASF SE: SEGMENTAL REVENUE

FIGURE 20 BASF SE: REGIONAL REVENUE

FIGURE 21 ASSOCIATED BRITISH FOODS PLC S: KEY FINANCIALS

FIGURE 22 ASSOCIATED BRITISH FOODS PLC: SEGMENTAL REVENUE

FIGURE 23 ASSOCIATED BRITISH FOODS PLC: REGIONAL REVENUE

FIGURE 24 SIGNET EXCIPIENTS PVT. LTD (IMCD): KEY FINANCIALS

FIGURE 25 SIGNET EXCIPIENTS PVT. LTD (IMCD): SEGMENTAL REVENUE

FIGURE 26 SIGNET EXCIPIENTS PVT. LTD (IMCD): REGIONAL REVENUE

FIGURE 27 SIGACHI INDUSTRIES LIMITED: KEY FINANCIALS

FIGURE 28 SIGACHI INDUSTRIES LIMITED: SEGMENTAL REVENUE

FIGURE 29 SIGACHI INDUSTRIES LIMITED: REGIONAL REVENUE

FIGURE 30 SPECTRUM CHEMICAL MANUFACTURING CORP.: KEY FINANCIALS

FIGURE 31 SPECTRUM CHEMICAL MANUFACTURING CORP.: SEGMENTAL REVENUE

FIGURE 32 SPECTRUM CHEMICAL MANUFACTURING CORP.: REGIONAL REVENUE

FIGURE 33 ROQUETTE FRÈRES: KEY FINANCIALS

FIGURE 34 ROQUETTE FRÈRES: SEGMENTAL REVENUE

FIGURE 35 ROQUETTE FRÈRES: REGIONAL REVENUE

FIGURE 36 CLARIANT: KEY FINANCIALS

FIGURE 37 CLARIANT: SEGMENTAL REVENUE

FIGURE 38 CLARIANT: REGIONAL REVENUE

FIGURE 39 DFE PHARMA: KEY FINANCIALS

FIGURE 40 DFE PHARMA: SEGMENTAL REVENUE

FIGURE 41 DFE PHARMA: REGIONAL REVENUE

FIGURE 42 J. RETTENMAIER & SÖHNE GMBH + CO KG: KEY FINANCIALS

FIGURE 43 J. RETTENMAIER & SÖHNE GMBH + CO KG: SEGMENTAL REVENUE

FIGURE 44 J. RETTENMAIER & SÖHNE GMBH + CO KG: REGIONAL REVENUE

FIGURE 45 EVONIK INDUSTRIES AG: KEY FINANCIALS

FIGURE 46 EVONIK INDUSTRIES AG: SEGMENTAL REVENUE

FIGURE 47 EVONIK INDUSTRIES AG: REGIONAL REVENUE

Biopharmaceutical Excipients Market

The biopharmaceutical excipients market is grow at a CAGR of~6.8% to hit USD 3,114.6 million by 2027

Segmentation

By Product Solubilizers & Surfactants/Emulsifiers (Triglycerides Esters) Polyols (Mannitol Sorbitol) Carbohydrates (Sucrose Dextrose Starch) Specialty Excipients
By Formulation Oral Topical Injectables

Key Players

  • Merck KGaA (Germany)
  • Colorcon (BPSI Holdings Inc)(.S)
  • BASF SE(Germany)
  • Associated British Foods plc (UK)
  • Signet Excipients Pvt. Ltd (IMCD) (Netherlands)
  • Sigachi Industries Limited (India)
  • Spectrum Chemical Manufacturing Corp. (US)
  • Roquette Frères (France)
  • Clariant (Switzerland)
  • DFE Pharma (Germany)

Drivers

  • Increasing demand of sucrose based excipients for medicine formulation
  • Growing demand for lipid excipient for the production of COVID vaccines
Speak to Analyst Request a Free Sample

Biopharmaceutical Excipients Market Overview:


The biopharmaceutical excipients market is expected to cross USD 3,114.6 million by 2027 at a CAGR of~6.8%. A biopharmaceutical excipient is an inert drug delivery substance methodologically prepared with the medically active ingredient that further processes the drug delivery in the recipient's system. Excipients are stable and reproducible, pharmacologically inert, and cost-effective. They are composed of corn, wheat, sugar, minerals, and othersuch substances. Biopharmaceutical excipients are available in different types of formulations such as capsules, topical creams, tablets, gels, injectables, and transdermal patches. In addition, these types of excipients provide accurate dosing of potent ingredients, offer mechanical strength to the ingredients, increase the surface area for the active ingredient, protect the medication from the environmental reaction, and mask the texture, smell, and taste of the drug.


Biopharmaceutical excipients are experiencing high demand due to increasing production of drugs during the pandemic outbreak, supporting government policies, and introduction of partial subsidy schemes minimizing production costs. The outbreak of the coronavirus across the globe created huge demands for specialized medicines that further drive excipient sales. The market players offer specific excipients for biopharmaceuticals that are composed of sucrose, sodium chloride, magnesium chloride hexahydrate, and disodium edetate dehydrate. Moreover, the increasing number of patients getting diagnosed with chronic disease is creating possibilities for the biopharmaceutical excipients manufacturers. The market growth is driven by the above-mentioned factors and is expected to accelerate during the forecast period.


COVID-19 Analysis


COVID-19 has impacted various industry verticals across the globe. The pandemic spread led to the closure of manufacturing units, transportation of raw materials, and distribution channels throughout the globe. During the initial days of lockdown, the production of drugs and health-related products ceased to avoid the spread of disease. The government authorities mandate the guidelines to restrict the ongoing R&D activities and biopharmaceutical manufacturing. However, the demand for generic and specialty medicines rose due to the increasing number of corona cases and existing patients diagnosed with chronic diseases. The pharmaceutical production was carried out with special guidelines, and the research laboratories were functional with a limited workforce.


The increasing number of COVID cases impulsed government authorities to manufacture drugs in a large volume to treat the affected patients. However, the manufacturing units were working with a low workforce as the employees and daily wagers traveled back to their hometown, limiting the production capacity of the organizations. The government authorities promised to provide meals, insurance and, higher wages for immediate deployment of the workforce in pharmaceutical manufacturing units. This created an opportunity for the biopharmaceutical excipient manufacturers and augmented the product sales during the pandemic outbreak.


Market Dynamics


Drivers


Increasing demand for sucrose-based excipients for medicine formulation



  • Sucrose is made up of glucose and fructose extracted from sugar cane and sugarbeets. It has a non-reducing crystalline disaccharide property that stabilizes the protein, lipids, and carbohydrates throughout the formulation stage of therapeutics. Hence it is highly acclaimed in the biopharmaceutical industry. In addition, sucrose-based excipients are used in the biopharmaceutical industry for preserving stem cells, stabilizing antibody-drug conjugate, monoclonal antibody, peptide, and vaccine. The non-toxic property of the sugar and high availability are driving the demand for sucrose-based excipients. Biopharmaceutical manufacturers use sucrose in the form of chewable tablets, lozenges, and tablets for medicine formulation.

  • Companies such as DFE Pharma (Germany) offer BioHale Sucrose, low endotoxin sucrose that is used in formulating medicines. High demand for sucrose-based excipients is observed in the recent timelines owing to its distinctive physical and chemical properties, specifically in aqueous solutions. Additionally, sugar is highly recommended in stabilizing protein medicines as it forms a glassy sugar coating around the protein that hinders its molecular mobility. Sucrose-based excipients are used in various dosage forms, such as parenteral or oral solid.


Growing demand for lipid excipient for the production of COVID vaccines



  • In 2020, a large amount of the population was severely affected form the coronavirus that led to the high investment in R&D activities for the innovation of new vaccines, the establishment of new regulatory guidelines, and the development of new manufacturing capabilities. Biopharmaceutical manufacturers increased their research in the development of lipid nanoparticles for RNA vaccines. Companies such as Pfizer/BioNTech and Moderna developed large and fragile mRNA strands that use lipid-based excipients to stabilize the vaccine for COVID-19. They announced to manufacture 2 billion doses of vaccine and will be supported by the lipid excipients for its formulation. According to Pfizer/BioNTech, 2 metric tons of lipid excipients will be required for the formulation of 2 billion vaccines. Furthermore, the excipient manufacturers are expanding their manufacturing capabilities to fulfill the market demand. Such factors are augmenting the biopharmaceutical excipient market and are estimated to accelerate in the accessed time period.


Rising demand for stable and economical excipient for generic medicines


Market Restraints


Concerns pertaining to the adverse effects of biopharmaceutical excipients



  • The consumption of biopharmaceutical excipients may affect individuals differently. Dose per individual varies and may be toxic and hypersensitive after high consumption of the excipients-based biopharmaceuticals. High doses of medicines adversely affect infants and neonates. Moreover, incompatibilities between excipients and drugs can increase the rate of chemical degradation, forming more complex molecules making them toxic or allergic for administration. Furthermore, few individuals are allergic to the coloring agents, lactose, and other components used in the manufacturing of excipients. For instance, some people are allergic to tartrazine,which is a type of artificial coloring agent commonly used as a food dye. These common types of adverse effects and allergies might hamper the biopharmaceutical excipients market.


Technology Analysis


Nanotechnology is significantly being used in the development of advanced excipients. The use of nanotechnology will alter the size of the excipients from capsules and tablets to solidified micelles. The emergence of such technology aims to improve the drug delivery of medicines. Additionally, nanotech can be used to improve the hindered release of formulations. According to a study in the Journal of Pharmaceutical Sciences, the porous magnesium carbonate excipient can control the release of active pharmaceutical ingredients. Moreover, the introduction of 3D printing aims at augmenting the production of new generation excipient. It is used for the fabrication of the immediate release pharmaceutical tablets. The emergence of such technologies is propelling the biopharmaceutical excipients market.


Segment Overview


By Product



  • Solubilizers & Surfactants/Emulsifiers:Solubilizers are the substances that solubilize water-insoluble drugs, complexion, microemulsions, liposomes, emulsions, and micelles. Solubilizers are administered either orally or injected through veins and muscular or other passages. Solubilizers/emulsifiers are further categorized into triglycerides, esters, and others.

  • Polyols:This type of product is obtained through a biotechnological process with a highly effective and extremely reactive property. It has a limited quantity of reducing sugars hence is less reactive to amino groups and reducing sugars. Polyols are categorized into mannitol, sorbitol, and others.

  • Carbohydrates:It is an excipient made from carbohydrates such as sugar, starch, and fiber. These types of excipients are used as a sweetening agent, tablet and capsule diluent, tonicity agent, and vehicle for lyophilized preparation. Carbohydrate excipients are categorized into sucrose, dextrose, starch, and others.

  • Specialty Excipients:This type of excipient acts as binders, fillers, lubricants, and disintegrants.


By Formulation



  • Oral: It is a type of formulation that is administered orally and is engrossed through the intestine, stomach, or gastrointestinal tract. The oral formulations are taken in the form of tablets and capsules.

  • Topical:This type of formulation is produced using a base used for a particular site of the body or any kind of skin disorder. The product is designed to moisturize and amplify the diffusion of active ingredients.

  • Injectables:It is a kind of formulation that is stored in liquid and lyophilized forms. These types of formulations are administered through an intramuscular, intravenous, subcutaneous, and intra-articular stream.


Regional Analysis


North America


Increasing demand for medicines across the region is driving the North America biopharmaceutical excipients market


North America held the largest share of the global biopharmaceutical excipient market in 2020 due to the increasing manufacturing of generic and specialty drugs, growing investments in R&D activities, and the establishment of technically advanced research centers. The prominent players are involved in the diversification of their distribution channel and expansion of their manufacturing facilities across the region, engaging in mergers and acquisitions, and introduction of new product variants for business growth.


Asia Pacific


Supportive government policiesarepropelling the Asia-Pacific biopharmaceutical excipient market


The Asia-Pacific biopharmaceutical excipients market is projected to be the fastest-growing regional market due to the up-gradation of pharmaceutical manufacturing units, an increasing number of biopharmaceutical investors, supportive government policies for the production of medicines, and deployment of nanotech labs for innovation of advanced excipients. Moreover, other factors supporting the biopharmaceutical excipient market include substantial investments by industry players and the innovation of machines to produce a high volume of excipients in a limited time. Such factors are expected to propel the market growth during the forecast period.


Competitive Landscape


Colorcon (US) is one of the leading players in the biopharmaceutical excipients market, offering products such as starch 1500, startab, starcap, and ambaerlite, and duolite ion exchange resin. These excipients can stabilize moisture-sensitive drugs, offer low dose content uniformity, and are compliant with regulatory standards. In addition, products such as startab are compressible starch excipients that provide excellent flow and compressibility. The product is manufactured at GMP facilities and is compliant with government guidelines. Moreover, satrcap a maize starch excipient, offers high flow and low adhesion functionality. Starcap provides lasting stability to reactive drugs. Furthermore, the company introduced ion-exchange resin-based excipients that are applied for taste masking, solubility enhancing, drug stabilizing, and abuse deterrence.


Industry players are coming up with various commercial strategies to augment their market footprint. The organizations are capitalizing on innovations and product launches to expand their product portfolio, further driving the biopharmaceutical excipients market. In addition, the market players are offering contractual agreements, approvals from government authorities, collaborations, funding, product promotions, and partnering with other players to expand their global footprint.


List of Key Companies Covered in this Report:



  • Merck KGaA (Germany)

  • Colorcon (BPSI Holdings Inc)(.S)

  • BASF SE(Germany)

  • Associated British Foods plc (UK)

  • Signet Excipients Pvt. Ltd (IMCD) (Netherlands)

  • Sigachi Industries Limited (India)

  • Spectrum Chemical Manufacturing Corp. (US)

  • Roquette Frères (France)

  • Clariant (Switzerland)

  • DFE Pharma (Germany)

  • Rettenmaier & SöhneGmbh + Co Kg (Germany)

  • Evonik Industries AG (Germany)


Recent Developments

  • In May 2019,Colorcon, Inc. (US) launched a starch-based tableting excipient for direct compression. The product is developed using particle engineering and is approved by regulatory authorities across the globe.

  • In March 2020, Signet Chemical Corporation Pvt. Ltd(India) changed its name to Signet Excipients Pvt. Ltd.Furthermore, in November 2020, the company was acquired by IMCD N.V.(Netherlands),a leading global distributor of specialty chemicals and ingredients.

  • In September 2020,Sigachi Industries (India), a cellulose-based excipient manufacturer, filed an IPO worth USD 600 million.

  • In March 2020, Roquette (France) launched an online technical platform,"Innovation Hub,"for researchers and developersto formulate ideas and information exchange.

  • In April 2021,DFE Pharma (Germany) launched an excipient solution for biopharma,BioHale Sucrose,that offers exceptional purity stabilization for biologics.


Report Overview


The study covers the existing short-term and long-term market effect, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID on the market.


Scope of the Report & Segmentation


By Product



  • Solubilizers & Surfactants/Emulsifiers

    • Triglycerides

    • Esters

    • Others



  • Polyols

    • Mannitol

    • Sorbitol

    • Others



  • Carbohydrates

    • Sucrose

    • Dextrose

    • Starch

    • Others



  • Specialty Excipients


By Formulation



  • Oral

  • Topical

  • Injectables



Report Scope:
Report Attribute/Metric Details
  Market Size   2027:~USD 3,114.6Million
  CAGR   ~6.8%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018-2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Treatment Procedure, Cellulite Type and End Use
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Merck KGaA (Germany), Colorcon (BPSI Holdings Inc.) (U.S.), BASF SE(Germany), Associated British Foods plc (UK), Signet Excipients Pvt. Ltd (IMCD) (Netherlands), Sigachi Industries Limited (Hyderabad), Spectrum Chemical Manufacturing Corp. (U.S.), Roquette Frères (Roquette Frères) Clariant (Switzerland), DFE Pharma (Germany) J. Rettenmaier&SöhneGmbh + Co Kg (Germany) Evonik Industries AG (Germany)
  Key Market Opportunities   The emrgence of 3D pinters for customized drug manufacturing
  Key Market Drivers   Increasing demand of sucrose based excipients for medicine formulation


Speak to Analyst Ask for Customization